Generate a tailored SOP for Dr. Harry Erba. Improve your application with a focused, well-structured draft.
Harry Paul Erba is a Professor of Medicine at the Duke Cancer Institute and serves as the Director of the Leukemia Program. His research primarily focuses on the clinical development of novel therapies for various hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. He has taken a lead role as Principal Investigator, working on small molecular inhibitors and antibody-drug conjugates to improve patient outcomes. Dr. Erba is a respected member of the SWOG Leukemia Committee and maintains an active presence in the academic community since joining the Duke Cancer Institute in 2018. He earned both his Ph.D. and M.D. from Stanford University in 1988, followed by a clinical fellowship at Harvard Medical School. His extensive training and experience have positioned him as a significant contributor to advancements in hematologic oncology.
Duke Cancer Institute • Durham, NC
Clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy, leading research and clinical initiatives.
Department of Biomedical Engineering (MS program)